Tech Entrepreneur Creates Dog Cancer Vaccine with ChatGPT

Mar 20, 2026, 2:30 AM

Hover over text to view sources

In a remarkable blend of technology and compassion, Australian tech entrepreneur Paul Conyngham has successfully created a personalized mRNA vaccine for his dog, Rosie, who was diagnosed with terminal mast cell cancer. This pioneering effort has sparked interest in the potential for similar treatments in humans.

Rosie, an 8-year-old black Staffordshire terrier-Shar Pei mix, faced a dire prognosis after months of chemotherapy and surgery yielded little progress. Conyngham, unwilling to accept the grim diagnosis, turned to ChatGPT for assistance in developing a viable treatment. His journey began with a DNA sequencing project at the University of New South Wales (UNSW), where he aimed to identify mutations responsible for Rosie's cancer.

After investing around $3,000 AUD in sequencing Rosie's tumor DNA, Conyngham leveraged his 17 years of experience in machine learning and data analysis. He utilized AI algorithms, including Google DeepMind's AlphaFold, to analyze the genetic data and identify potential drug targets, ultimately leading to the design of a custom mRNA vaccine.

Conyngham expressed a deep emotional connection to Rosie, stating, "Rose is my best mate. She's been with me through breakups, tough business deals, and forest walks. When she was given this sentence, I had to do everything I could for her." This sentiment fueled his determination to explore cutting-edge solutions for her condition.

The innovative approach faced several challenges, including obtaining ethics approval for the treatment trial. Conyngham noted that navigating the regulatory landscape was "actually harder than the vaccine creation." With support from the UNSW team and canine immunotherapy expert Rachel Allavena, he persevered through a lengthy approval process, which ultimately allowed Rosie to receive her first shot in December 2022, followed by a booster shot in early 2023.

The results of this personalized treatment have been promising. Initially presenting a tennis-ball-sized tumor, Rosie has seen her cancerous growth shrink by approximately 75%. Conyngham reported that the treatment has significantly improved her quality of life, with increased energy and a happier demeanor, stating, "I'm under no illusion that this is a cure, but I do believe this treatment has bought Rosie significantly more time and quality of life.".

Pall Thordarson, director of the UNSW RNA Institute, emphasized the significance of this achievement, labeling it as the "first personalized cancer vaccine designed for a dog." He expressed hope that the success of such treatments could pave the way for similar advancements in human medicine, asking, "If we can do this for a dog, why aren't we rolling this out to all humans with cancer?".

Conyngham's innovative use of AI has captured the attention of the tech community, with figures like OpenAI President Greg Brockman praising the project as a groundbreaking application of artificial intelligence in healthcare.

As Conyngham continues to work on a second vaccine for another tumor that did not respond to the initial treatment, the implications of this case extend beyond just canine health. The evolving landscape of personalized medicine, driven by advancements in AI and genetic research, offers a glimpse into a future where targeted therapies may become increasingly accessible for both pets and humans.

In summary, the story of Rosie and her custom mRNA vaccine illustrates not only the potential for technological innovation in veterinary medicine but also raises vital questions about the future of cancer treatment for humans. As research progresses, Conyngham's experience may inspire similar endeavors in the broader medical community, ultimately aiming to improve the lives of both animals and humans facing cancer diagnoses.

With Rosie now more energetic and healthier, this journey highlights the power of technology to create hope and change lives, one paw at a time.

Amazon Expands Health AI Access for Virtual Health Care

Amazon is broadening access to its Health AI virtual assistant, now available to most US customers through the Amazon app and website. This tool provides personalized health guidance and connects users to medical professionals, aiming to enhance health care accessibility.

Amazon Expands Access to Health AI Assistant for All U.S. Consumers

Amazon has broadened the availability of its Health AI assistant, previously exclusive to One Medical members, to all US consumers. This tool enables users to ask health-related questions, manage appointments, and receive personalized medical guidance without needing a Prime subscription.

Yann LeCun's AMI Secures $1 Billion Funding for Health AI Innovations

Advanced Machine Intelligence (AMI), co-founded by Yann LeCun, has raised over $1 billion to develop AI systems focused on world models. This funding, the largest seed round in Europe, will enhance healthcare workflows through partnerships with companies like Nabla.

Google and Taiwan Collaborate on AI-Driven Public Health Solutions

Google and Taiwan's National Health Insurance Administration are partnering to implement AI technology to enhance public health initiatives, particularly in diabetes care. This collaboration leverages extensive health data to create a predictive model that significantly improves risk assessment efficiency, potentially serving as a global blueprint for proactive healthcare.

Humanizing AI: An Ethical Approach in the Care Economy

AI has the potential to transform the care economy by enhancing efficiency and decision-making. However, ethical concerns regarding bias, human interaction, and transparency must be addressed to humanize these technologies effectively.